Research map: Characterization of US patients with alpha-1 antitrypsin deficiency treated with an alpha-1 proteinase inhibitor

Back to the article

Papers in this map

  1. Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries · Hude Quan · 2011 · 6050 citations · Cited by this paper
  2. Response to Kirshner et al.: updated cost consequence analyses using requested inputs · 2026 · Related
  3. Continuous or Nocturnal Oxygen Therapy in Hypoxemic Chronic Obstructive Lung Disease · NOCTURNAL OXYGEN THERAPY TRIAL GROUP · 1980 · 2226 citations · Cited by this paper
  4. Clinical burden and healthcare resource utilization after allogeneic hematopoietic stem cell transplant for sickle cell disease or β-thalassemia · 2026 · Related
  5. A Review of α1-Antitrypsin Deficiency · James K. Stoller · 2011 · 419 citations · Cited by this paper
  6. Cost-effectiveness of vagus nerve-mediated neuroimmune modulation for the treatment of moderate-to-severe rheumatoid arthritis · 2026 · Related
  7. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult · Robert A. Sandhaus · 2016 · 219 citations · Cited by this paper
  8. Interpreting per-death productivity estimates in human capital analyses of lung cancer: the role of working-age-restricted denominators · 2026 · Related
  9. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences · Laura Fregonese · 2008 · 213 citations · Cited by this paper
  10. An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma · 2026 · Related
  11. Values and Pitfalls of the Use of Administrative Databases for Outcomes Assessment · Emilie K. Johnson · 2013 · 204 citations · Cited by this paper
  12. Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis · 2026 · Related
  13. Two-year results after lung volume reduction surgery in alpha1-antitrypsin deficiency versus smoker's emphysema · PC Cassina · 1998 · 100 citations · Cited by this paper
  14. A system dynamics modelling protocol to evaluate the impact of a health financing mechanism for breast cancer pharmacotherapies in Malaysia · 2026 · Related
  15. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review · Ross Gareth Edgar · 2017 · 85 citations · Cited by this paper
  16. The financial impact of surgical interventions for benign prostatic hyperplasia within a single NHS trust · 2026 · Related
  17. The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database · Timm Greulich · 2016 · 83 citations · Cited by this paper
  18. From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis · 2026 · Related
  19. Lung Volume Reduction Surgery in Patients With Emphysema and α-1 Antitrypsin Deficiency · James K. Stoller · 2006 · 81 citations · Cited by this paper
  20. Cost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia · 2026 · Related
  21. Disease associations in alpha-1-antitrypsin deficiency · Helen Stone · 2013 · 57 citations · Cited by this paper
  22. Multi-Center Study: The Biochemical Efficacy, Safety and Tolerability of a New α1-Proteinase Inhibitor, Zemaira · James M. Stocks · 2006 · 56 citations · Cited by this paper
  23. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study · James M. Stocks · 2010 · 38 citations · Cited by this paper
  24. Long-term results of lung volume reduction surgery · T Fujimoto · 2002 · 38 citations · Cited by this paper
  25. The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency · Vickram Tejwani · 2021 · 34 citations · Cited by this paper
  26. Prevalence of Alpha-1 Antitrypsin Deficiency, Self-Reported Behavior Change, and Health Care Engagement Among Direct-to-Consumer Recipients of a Personalized Genetic Risk Report · James R. Ashenhurst · 2021 · 34 citations · Cited by this paper
  27. An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency · Amy Houghton Attaway · 2019 · 28 citations · Cited by this paper
  28. Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives · Mark Quinn · 2020 · 26 citations · Cited by this paper
  29. Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what’s down the road? · Franck Rahaghi · 2021 · 26 citations · Cited by this paper
  30. Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US · Robert A. Sandhaus · 2020 · 23 citations · Cited by this paper
  31. Biochemical Efficacy and Safety of a New, Ready-to-Use, Liquid Alpha-1-Proteinase Inhibitor, GLASSIA (Alpha 1 -Proteinase Inhibitor (Human), Intravenous) · Robert A. Sandhaus · 2013 · 20 citations · Cited by this paper
  32. Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint · Marc Miravitlles · 2023 · 20 citations · Cited by this paper
  33. Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic · Felix J.F. Herth · 2021 · 15 citations · Cited by this paper
  34. Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline · Paul Hernandez · 2025 · 13 citations · Cited by this paper
  35. Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States · Jan Sieluk · 2020 · 12 citations · Cited by this paper
  36. Alpha-1 Antitrypsin Deficiency-Associated Clinical Manifestations and Healthcare Resource Use in the United States · Ernesto Mayen Herrera · 2021 · 7 citations · Cited by this paper
  37. Assessment of Patient Perspectives and Barriers to Self-Infusion of Augmentation Therapy for Alpha-1 Antitrypsin Deficiency During the COVID-19 Pandemic · Jacob Colello · 2022 · 7 citations · Cited by this paper
  38. Detecting Alpha-1 Antitrypsin Deficiency: Current State, Impediments, Opportunities, and Future Directions · James K. Stoller · 2024 · 7 citations · Cited by this paper
  39. Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy · Michael Campos · 2017 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)